In pancreatic cancer, neuroblastoma, and glioblastoma xenograft models, CAR T cells incorporating the lead human binder Y111 were well tolerated and demonstrated superior antitumor activity compared with 376.96- and MGA271-based CARs. Y111 CAR treatment induced complete responses, tumor rejection, and significant survival benefits, identifying Y111 as a promising fully human B7-H3 CAR for solid tumors.

P1/2, N=61, Recruiting, Radiopharm Theranostics, Ltd | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026

In our experience, MYCN amplification and concomitant extra-CNS metastases at CNS relapse significantly decrease OS. Multimodal treatment, including 131I-omburtamab radioimmunotherapy, significantly improves survival outcomes.

P1/2, N=28, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | N=128 --> 28 | Trial completion date: Jun 2026 --> Mar 2025 | Trial primary completion date: Oct 2025 --> Mar 2025

P1/2, N=61, Not yet recruiting, Radiopharm Theranostics, Ltd

P1/2, N=69, Terminated, Takeda | Active, not recruiting --> Terminated; Terminated due to limited anti-cancer activity

B7-H3 is expressed on a high proportion of pediatric solid tumors. While enoblituzumab could be safely administered at a weekly dose of 15 mg/kg, no objective tumor responses were observed. Alternative strategies to target B7-H3 in children with relapsed solid tumors should be considered.

P1, N=60, Completed, Xencor, Inc. | Active, not recruiting --> Completed

P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jul 2025 --> Jul 2026

P2, N=31, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026

Overall, our findings highlight the potential of CC-3 for clinical evaluation as a therapeutic option for patients with endometrial cancer.

P2, N=200, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.